医学
肝硬化
肝细胞癌
非酒精性脂肪肝
重症监护医学
疾病
药品
内科学
纤维化
肝病
脂肪肝
胃肠病学
药理学
作者
Natalia Mazzella,Laura Maria Ricciardi,Arianna Mazzotti,Giulio Marchesini
标识
DOI:10.1016/j.cld.2013.09.005
摘要
The article is intended to provide an overview of the strengths and limits of controlled trials of pharmacologic treatment of nonalcoholic fatty liver disease. No drug has so far been approved, although validated on histologic outcomes. Several new drugs are under scrutiny, acting with different mechanisms along the chain of events from fatty liver to fibrosis, cirrhosis, and hepatocellular carcinoma. The article investigates which drug, if any, should be preferred for a tailored intervention in individual patients, according to age, comorbidities, and disease severity, and if treatment should be continued lifelong, to prevent disease progression and long-term occurrence of cirrhosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI